Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Treatment of MDR-TB using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules.

Bolhuis MS, van der Werf TS, Kerstjens HAM, de Lange WCM, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Aug 22. pii: 1900580. doi: 10.1183/13993003.00580-2019. [Epub ahead of print] No abstract available.

PMID:
31439686
2.

Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.

Dekkers BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, van der Werf TS, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Sep 5;54(3). pii: 1900373. doi: 10.1183/13993003.00373-2019. Print 2019 Sep. No abstract available.

PMID:
31048350
3.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):253-254. doi: 10.1097/FTD.0000000000000597. No abstract available.

PMID:
30883521
4.

Tuberculosis-Related Malnutrition: Public Health Implications.

Ter Beek L, Alffenaar JC, Bolhuis MS, van der Werf TS, Akkerman OW.

J Infect Dis. 2019 Jun 19;220(2):340-341. doi: 10.1093/infdis/jiz091. No abstract available.

PMID:
30835281
5.

Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625.

PMID:
30496467
6.

Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.

Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JC.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S303-S307. doi: 10.1093/cid/ciy613.

PMID:
30496466
7.

Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May.

8.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

9.

Lack of penetration of amikacin into saliva of tuberculosis patients.

van den Elsen SHJ, Akkerman OW, Huisman JR, Touw DJ, van der Werf TS, Bolhuis MS, Alffenaar JC.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702024. doi: 10.1183/13993003.02024-2017. Print 2018 Jan. No abstract available.

10.

In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC, van Soolingen D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01724-17. doi: 10.1128/AAC.01724-17. Print 2018 Mar.

11.

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.

van den Elsen SHJ, Oostenbrink LM, Heysell SK, Hira D, Touw DJ, Akkerman OW, Bolhuis MS, Alffenaar JC.

Ther Drug Monit. 2018 Feb;40(1):17-37. doi: 10.1097/FTD.0000000000000462. Review.

12.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
13.

Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.

Van Kampenhout E, Bolhuis MS, Alffenaar JC, Oswald LM, Kerstjens HA, de Lange WC, van der Werf TS, Akkerman OW.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601724. doi: 10.1183/13993003.01724-2016. Print 2017 Mar. No abstract available.

14.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

15.

Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring.

Bolhuis MS, Akkerman OW, Sturkenboom MG, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S44-S45. doi: 10.1016/j.ijmyco.2016.07.003. Epub 2016 Aug 8.

16.

Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements.

Sturkenboom MG, Bolhuis MS, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1695-1696. No abstract available.

PMID:
27931348
17.

Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.

van Altena R, Akkerman OW, Alffenaar JC, Kerstjens HA, Magis-Escurra C, Boeree MJ, van Soolingen D, de Lange WC, Bolhuis MS, Hoefsloot W, de Vries G, van der Werf TS.

Eur Respir J. 2016 Dec;48(6):1800-1802. doi: 10.1183/13993003.01208-2016. Epub 2016 Oct 6. No abstract available.

18.

Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?

Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW.

Eur Respir J. 2016 Apr;47(4):1288-90. doi: 10.1183/13993003.02185-2015. No abstract available.

19.

Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.

Ghimire S, Bolhuis MS, Sturkenboom MG, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Jun;47(6):1867-9. doi: 10.1183/13993003.00040-2016. Epub 2016 Mar 17. No abstract available.

20.

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.

Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W, van Soolingen D, Alffenaar JW.

Expert Opin Drug Metab Toxicol. 2016 May;12(5):509-21. doi: 10.1517/17425255.2016.1162785. Epub 2016 Mar 24. Review.

PMID:
26950189
21.

Emerging drugs and alternative possibilities in the treatment of tuberculosis.

Hofman S, Segers MM, Ghimire S, Bolhuis MS, Sturkenboom MG, Van Soolingen D, Alffenaar JW.

Expert Opin Emerg Drugs. 2016;21(1):103-16. doi: 10.1517/14728214.2016.1151000. Epub 2016 Feb 20. Review.

PMID:
26848966
22.

End TB with precision treatment!

van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC, Cobelens FG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Feb;47(2):680-2. doi: 10.1183/13993003.01285-2015. No abstract available.

23.

Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis.

Akkerman OW, Odish OF, Bolhuis MS, de Lange WC, Kremer HP, Luijckx GJ, van der Werf TS, Alffenaar JW.

Clin Infect Dis. 2016 Feb 15;62(4):523-4. doi: 10.1093/cid/civ921. Epub 2015 Nov 3. No abstract available.

PMID:
26534926
24.

Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.

Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW.

Eur Respir J. 2015 Oct;46(4):1205-7. doi: 10.1183/13993003.00606-2015. Epub 2015 Jul 9. No abstract available.

25.

Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future.

Sturkenboom MG, Akkerman OW, Bolhuis MS, de Lange WC, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Apr;59(4):2474. doi: 10.1128/AAC.05173-14. No abstract available.

26.

Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.

Hofman S, Bolhuis MS, Koster RA, Akkerman OW, van Assen S, Stove C, Alffenaar JW.

Bioanalysis. 2015;7(4):481-95. doi: 10.4155/bio.14.318. Review.

PMID:
25747766
27.

Breakpoints and drug exposure are inevitably closely linked.

Alffenaar JW, Akkerman OW, Bolhuis MS, Boeree MJ, de Lange WC, van der Werf TS.

Antimicrob Agents Chemother. 2015 Feb;59(2):1384. doi: 10.1128/AAC.04485-14. No abstract available.

28.

In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis.

Bolhuis MS, van der Laan T, Kosterink JG, van der Werf TS, van Soolingen D, Alffenaar JW.

Eur Respir J. 2014 Sep;44(3):808-11. doi: 10.1183/09031936.00041314. Epub 2014 May 2. No abstract available.

29.

Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS.

Vu DH, Koster RA, Bolhuis MS, Greijdanus B, Altena RV, Nguyen DH, Brouwers JR, Uges DR, Alffenaar JW.

Talanta. 2014 Apr;121:9-17. doi: 10.1016/j.talanta.2013.12.043. Epub 2013 Dec 27.

PMID:
24607103
30.

Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response.

Akkerman OW, van Altena R, Bolhuis MS, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2014;58(1):628. doi: 10.1128/AAC.01535-13. No abstract available.

31.

Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis.

Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2013 Aug;57(8):3676-80. doi: 10.1128/AAC.00558-13. Epub 2013 May 20.

32.

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients.

Bolhuis MS, van Altena R, van Soolingen D, de Lange WC, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2013 Dec;42(6):1614-21. doi: 10.1183/09031936.00001913. Epub 2013 Mar 21.

33.

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB.

Eur Respir J. 2013 Jun;41(6):1386-92. doi: 10.1183/09031936.00124312. Epub 2012 Sep 20.

34.

Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R, Brouwers JR, Uges DR, Alffenaar JW.

Antimicrob Agents Chemother. 2012 Nov;56(11):5758-63. doi: 10.1128/AAC.01054-12. Epub 2012 Aug 27.

35.

Linezolid: safety and efficacy monitoring.

Bolhuis MS, Pranger AD, Alffenaar JW.

Eur Respir J. 2012 May;39(5):1275-6; author reply 1276-7. doi: 10.1183/09031936.00200911. No abstract available.

36.

Comment on: daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.

Bolhuis MS, van Altena R, Alffenaar JW.

J Antimicrob Chemother. 2012 Aug;67(8):2055-6; author reply 2056-7. doi: 10.1093/jac/dks154. Epub 2012 Apr 27. No abstract available.

PMID:
22544851
37.

Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams.

Bolhuis MS, Panday PN, Pranger AD, Kosterink JG, Alffenaar JC.

Pharmaceutics. 2011 Nov 18;3(4):865-913. Review.

38.

Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Bolhuis MS, Panday PN, Pranger AD, Kosterink JG, Alffenaar JW.

Pharmaceutics. 2011 Nov 18;3(4):865-913. doi: 10.3390/pharmaceutics3040865.

39.

Clarithromycin significantly increases linezolid serum concentrations.

Bolhuis MS, van Altena R, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2010 Dec;54(12):5418-9. doi: 10.1128/AAC.00757-10. Epub 2010 Sep 13. No abstract available.

Supplemental Content

Loading ...
Support Center